Experience with Oritavancin therapy in invasive gram-positive infections

0

The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses” Stewart et al (2017).

Abstract:

INTRODUCTION: Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfortunately, data for using oritavancin in these populations are limited.

METHODS: We report ten cases of oritavancin use for invasive Gram-positive infections in our health system, and provide a review of the currently available literature regarding oritavancin therapy for invasive infections.

RESULTS: Among the ten patients who received oritavancin, the most common infection was methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia (n = 5, 50%). Other indications for oritavancin use included methicillin-resistant S. aureus (MRSA) bursitis (n = 1, 10%), group B streptococcal bacteremia with native tricuspid valve infective endocarditis (n = 1, 10%), coagulase-negative staphylococcal bacteremia (n = 1, 10%), MSSA deep tissue infection (n = 1, 10%), and enterococcal bacteremia (n = 1, 10%). Oritavancin was well tolerated, and 7/10 (70%) patients were successfully treated.

CONCLUSION: Oritavancin is a potential option for patients with invasive Gram-positive infections. Further study is warranted.

Reference:

Stewart, C.L., Turner, M.S., Frens, J.J., Snider, C.B. and Smith, J.R. (2017) Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections. Infectious Diseases and Therapy. April 6th. .

doi: 10.1007/s40121-017-0156-z.

Thank you to our partners for supporting IVTEAM

Share.

Comments are closed.